GTBP
GT Biopharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$13.04M
P/E Ratio
—
EPS
$-6.68
Beta
1.20
52W High
$3.85
52W Low
$0.39
50-Day MA
$0.49
200-Day MA
$1.01
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
17.33
PEG Ratio
1.05
About GT Biopharma Inc
GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its patented immune-enhancer cell fusion protein Tri-specific Killer Engager (TriKE) technology platform. The company is headquartered in Beverly Hills, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-6.76M |
| Operating Margin | 0.00% |
| Return on Equity | -1377.00% |
| Return on Assets | -125.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.23 |
| Price-to-Book | 2.42 |
| Price-to-Sales (TTM) | 204.96 |
| EV/Revenue | 773.27 |
| EV/EBITDA | -0.09 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $31.55M |
| Float | $30.83M |
| % Insiders | 3.91% |
| % Institutions | 4.33% |
Data last updated: 4/8/2026